Optimi Health welcomes expanded Australian Authorized Prescriber framework for psilocybin and MDMA

Optimi Health Corp. (OPTH) — Optimi Health highlighted final recommendations from Australia's Therapeutic Goods Administration that broaden the Authorized Prescriber scheme for psilocybin (for treatment-resistant depression) and MDMA (for PTSD), widening therapist eligibility and accepted treatment settings.

Optimi supplies both products into Australia from its GMP facility in Canada. The expansion supports demand for the company's finished psychedelic drug products in the world's leading regulated prescription market, where coverage now spans private insurers and public schemes such as the DVA and NDIS.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.